Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | AR | P10275 | 13/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.53 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2614475 | 0.88 | AR (0.69) | ALDH1A1KDM4EUSP2ARACHE | |
| Thianthrene SCHEMBL30427863 | 0.87 | ALDH1A1 (0.50) | ALDH1A1KDM4EUSP2ARACHE | |
| SCHEMBL1003862 | 0.84 | ALDH1A1 (0.46) | ALDH1A1KDM4EUSP2AR | |
| SCHEMBL22184957 | 0.82 | POLB (0.63) | ALDH1A1KDM4EUSP2ARACHE | |
| SCHEMBL17986256 | 0.82 | AR (0.45) | ALDH1A1KDM4EUSP2ARACHE | |
| SCHEMBL15298755 | 0.80 | AR (0.59) | ALDH1A1KDM4EUSP2ARIMPDH2 | |
| SCHEMBL15832015 | 0.79 | PRKCQ (0.55) | ALDH1A1KDM4EUSP2ARACHE | |
| SCHEMBL16952923 | 0.79 | ACHE (0.56) | ALDH1A1KDM4EUSP2ARACHE | |
| SCHEMBL19757165 | 0.79 | ACHE (0.56) | ALDH1A1KDM4EUSP2ARACHE | |
| SCHEMBL30730992 | 0.79 | ALDH1A1 (0.63) | ALDH1A1KDM4EUSP2ARIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129016-A1 | PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-04-24 | — | — | US | disclosed |
| EP-4400172-A2 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-11608322-B2 | Reagents and process for direct C—H functionalization | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-03-21 | — | — | US | disclosed |
| EP-3350170-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-01-26 | — | — | EP | disclosed |
| US-20220002263-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2022-01-06 | — | — | US | disclosed |
| EP-3715347-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3350177-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-07-07 | — | — | EP | disclosed |
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| EP-1219609-B1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-1983000333-A1 | ANTI-HYPERTENSOR, HETEROCYCLICALLY DI-ORTHOSUBSTITUTED PHENOLS | TEULON, JEAN-MARIE | 1983-02-03 | — | — | WO | disclosed |
| EP-0070779-A2 | Di-ortho-substituted phenols of which one of the substitutions is a heterocycle, process for their preparation, anti-hypertensive medicines containing them and synthesis intermediates | CARPIBEM (CENTRE D'ACTIVITE ET DE RECHERCHE PHARMACEUTIQUE INDUSTRIELLE BIOLOGIQUE ET MEDICALE) Société Anonyme dite: (FR) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002263-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | CFH, DOHH, CTSH | ALDH1A1 283/4885KDM4E 739/4885USP2 819/4885 |
| US-20250129016-A1 | PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF | RCC2, PPOX, FTO | ALDH1A1 2660/4885KDM4E 290/4885USP2 4032/4885 |
| US-11608322-B2 | Reagents and process for direct C—H functionalization | CFH, DOHH, CTSH | ALDH1A1 287/4885KDM4E 698/4885USP2 807/4885 |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | ALDH1A1 3742/4885KDM4E 881/4885USP2 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.